Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
$58.62
$1.11(1.83%)
At close: 4:00 PM EDT
$58.62
$1.11(1.83%)
Day’s Range― - ―
52-Week Range$42.52 - $62.89
Previous CloseN/A
Volume5.70M
Average Volume (3M)12.95M
Market Cap
$119.69B
Enterprise Value$156.31B
Total Cash (Recent Filing)$10.67B
Total Debt (Recent Filing)$47.14B
Price to Earnings (P/E)15.6
Beta0.26
Next Earnings
Apr 30, 2026EPS Estimate
1.42Next Dividend Ex-DateN/A
Dividend Yield4.11%
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,041,735,500
10 Day Avg. Volume9,816,150
30 Day Avg. Volume12,946,058
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue3.24
Enterprise Value/Gross Profit4.79
Enterprise Value/Ebitda10.75
Forecast
1Y Price Target
$62.39Price Target Upside6.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)6.27
Revenue Forecast (FY)$47.01B
Bulls Say, Bears Say
Bulls Say
CELMoD Clinical EfficacyAnalyst notes Phase III EXCALIBER-RRMM showed a statistically significant improvement in minimal residual disease negativity for iberdomide plus Darzalex, indicating meaningful disease control that could support broader adoption of CELMoD therapies.
Eliquis Pricing Boost And GuidanceAnalyst points out that one-time US pricing adjustments removed certain rebate and penalty liabilities for the leading anticoagulant, lifting revenue expectations and underpinning guidance that exceeded consensus.
Regulatory Momentum For IberdomideAnalyst highlights that the FDA accepted the NDA for iberdomide using minimal residual disease as an endpoint and granted breakthrough therapy designation, signaling regulatory recognition that could expedite market access if approval is secured.
Bears Say
Approval Risk Tied To Survival DataAnalyst warns that overall survival and confirmatory outcomes remain pending, creating uncertainty about converting accelerated approvals into full approvals and the drug's ultimate commercial impact.
Clinical Safety And Tolerability ConcernsAnalyst cautions that choosing a lower iberdomide dose suggests potential toxicity issues, with prior neutropenia observations that could limit tolerability and constrain real-world use.
Loss Of Exclusivity And Generic ErosionAnalyst notes that the leading anticoagulant will face generic competition when exclusivity ends, posing a significant revenue erosion risk for the company.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.52 and its highest was $62.89 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $119.69B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 30, 2026 which is in 18 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 05, 2026. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.226 by $0.034.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.63 which represents an annual dividend yield of 4.11%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.42.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,041,735,500 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.26 in its last earnings report, beating expectations of $1.226. Following the earnings report the stock price went up 3.298%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.39 (6.43% Upside)
$62.39 (6.43% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 92%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.97%
12-Months-Change
Fundamentals
Return on Equity
39.27%
Trailing 12-Months
Asset Growth
-2.77%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. The company focuses on therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with a portfolio of branded medicines and biologics sold through healthcare providers, pharmacies, and hospitals worldwide.
BMY Company Deck
BMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$62.39
▲(6.43% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
19.16% Mutual Funds
14.39% Other Institutional Investors
38.83% Public Companies and Individual Investors